Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PHOTACs enable optical control of protein degradation
Martin Reynders, Bryan S. Matsuura, Marleen Bérouti, et al.
Science Advances (2020) Vol. 6, Iss. 8
Open Access | Times Cited: 226

Showing 26-50 of 226 citing articles:

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 123
CRL4AMBRA1 is a master regulator of D-type cyclins
Daniele Simoneschi, Gergely Róna, Nan Zhou, et al.
Nature (2021) Vol. 592, Iss. 7856, pp. 789-793
Open Access | Times Cited: 122
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 122
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
Jing Gao, Bo Hou, Qiwen Zhu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 116
Rational Design in Photopharmacology with Molecular Photoswitches
Piermichele Kobauri, Frank J. Dekker, Wiktor Szymański, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 30
Open Access | Times Cited: 104
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 92
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 87
Triggered azobenzene-based prodrugs and drug delivery systems
Jundong Zhu, Tao Guo, Zheng Wang, et al.
Journal of Controlled Release (2022) Vol. 345, pp. 475-493
Closed Access | Times Cited: 85
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 15, pp. 6234-6250
Open Access | Times Cited: 84
Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
Yongfeng Tao, David Remillard, Ekaterina V. Vinogradova, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 40, pp. 18688-18699
Open Access | Times Cited: 82
The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis
Kevin Dzobo, Collet Dandara
Biomimetics (2023) Vol. 8, Iss. 2, pp. 146-146
Open Access | Times Cited: 74
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
Mengyang Chang, Feng Gao, Devin S. Pontigon, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 25, pp. 14155-14163
Closed Access | Times Cited: 60
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
Chuanjie Chen, Yiwen Yang, Zhe Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8428-8440
Closed Access | Times Cited: 43
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 42
Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy
Xiao Cheng, Shiqi Hu, Ke Cheng
ACS Nano (2023) Vol. 17, Iss. 12, pp. 11855-11868
Closed Access | Times Cited: 41
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 29
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Yilin Chen, Haoan Xue, Jianping Jin
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107264-107264
Open Access | Times Cited: 16
PROTACs: A novel strategy for cancer therapy
Jing Liu, Jia Ma, Yi Liu, et al.
Seminars in Cancer Biology (2020) Vol. 67, pp. 171-179
Closed Access | Times Cited: 136
Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies
Michael L. Drummond, Andrew J. Henry, Huifang Li, et al.
Journal of Chemical Information and Modeling (2020) Vol. 60, Iss. 10, pp. 5234-5254
Open Access | Times Cited: 118
A caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Cyrille S. Kounde, Maria M. Shchepinova, Charlie N. Saunders, et al.
Chemical Communications (2020) Vol. 56, Iss. 41, pp. 5532-5535
Open Access | Times Cited: 103
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 95
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 91
Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia
Weiyan Cheng, Shasha Li, Xueqian Wen, et al.
Chemical Communications (2021) Vol. 57, Iss. 95, pp. 12852-12855
Closed Access | Times Cited: 67

Scroll to top